Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry
Alimentary Pharmacology & Therapeutics2022Vol. 57(1), pp. 117–126
Citations Over TimeTop 10% of 2022 papers
Tessa Straatmijer, Fiona D M van Schaik, Alexander Bodelier, Marijn C. Visschedijk, Annemarie C. de Vries, Cyriel Y. Ponsioen, Marieke Pierik, Adriaan A. van Bodegraven, Rachel West, Nanne K.H. de Boer, Nidhi Srivastava, Tessa E H Römkens, Jildou Hoekstra, Bas Oldenburg, Gerard Dijkstra, C. Janneke van der Woude, Mark Löwenberg, Zlatan Mujagic, Vince Biemans, Andrea E. van der Meulen‐de Jong, Marjolijn Duijvestein
Abstract
Tofacitinib was effective in 31.8% of patients after 24 months of treatment.
Related Papers
- → Sa1750 - The Effect of Tofacitinib on Serum Lipids and Cardiovascular Safety in Patients with Ulcerative Colitis - Results from the Tofacitinib Ulcerative Colitis Clinical Program(2018)1 cited
- → First Oral Drug for Moderate-To-Severe Ulcerative Colitis(2018)1 cited
- → 684 INCIDENCE OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL DEVELOPMENT PROGRAM: AN UPDATE AS OF MAY 2019(2020)
- → Tu1856 THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS - UPDATED RESULTS FROM THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM(2020)
- → Fr538 THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAM(2021)